Launched in support of the country’s most vulnerable communities amidst the ongoing economic crisis, the ‘Manudam Mehewara’ emergency relief initiative has reached its second milestone of providing emergency relief worth Rs. 125 million to over 50,000 families in need across the island, as of 7th June, 2022.

GDP accreditation shows that Hemas Pharmaceuticals follows the World Health Organisation's requirements for Good Distribution Practices of Pharmaceutical Products. Furthermore, this accreditation assures that quality management systems are consistent throughout the supply chain. Bureau Veritas is a prominent certification body that supports organisations all over the world to enhance their performance.


This humanitarian coalition initiated by Dialog Axiata PLC, MAS Holdings, Hemas Holdings PLC, CBL Group, Citi and Sunshine Holdings PLC along with execution partner Sarvodaya Shramadana Movement and independent auditor PwC Sri Lanka, aims to reach 200,000 vulnerable families and communities across the country that do not have access to essential supplies and basic necessities. ITN, Siyatha, Swarnawahini, TV Derana and Vasantham are also supporting the initiative as media partners.

Emergency relief is currently being distributed across all 25 districts, and the Manudam Mehewara programme will conduct its relief efforts until a sustainable benefit transfer system is established through an effective recovery plan. Manudam Mehewara invites all corporates to join its shared mission to support over 200,000 vulnerable families across Sri Lanka.